Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.46 |
| ▸ | TUBB | P07437 | 5/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1414594 | 0.98 | PTGS2 (0.47) | PTGS2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL16541886 | 0.83 | CA2 (0.53) | ABCB1CYP19A1KDM4EALDH1A1LMNA | |
| SCHEMBL12593861 | 0.82 | MAPT (0.35) | KDM4EKDM1ALMNAMAPTHPGD | |
| Bromide SCHEMBL16180801 | 0.81 | CA2 (0.52) | ABCB1CYP19A1KDM4EKDM1AALDH1A1 | |
| SCHEMBL5083307 | 0.79 | TSHR (0.47) | ABCB1CYP19A1ALDH1A1 | |
| Bromide SCHEMBL16180511 | 0.77 | TSHR (0.46) | ABCB1CYP19A1ALDH1A1 | |
| SCHEMBL13403262 | 0.77 | KDM1A (0.46) | KDM4EKDM1AALDH1A1MAPTHPGD | |
| SCHEMBL13432593 | 0.77 | KDM4E (0.42) | HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL5689879 | 0.76 | TUBB4A (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9088704 | 0.76 | GAA (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113501783-B | Erianin heterocyclic derivative and preparation method and application thereof | 上海应用技术大学 | 2022-11-15 | — | — | CN | claimed |
| EP-2065358-B1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) | 2015-07-08 | — | — | EP | claimed |
| CN-101085743-B | Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof | DADE PHARMACEUTICAL CO., LTD., ZHEJIANG PROV. (CN) | 2012-02-15 | — | — | CN | claimed |
| CN-101139358-B | Ethoxy combretastatin and preparation and use of its prodrug | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD | 2011-10-12 | — | — | CN | claimed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | claimed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | claimed |
| EP-2025661-B1 | FLUOROALKYLOXY-CONTAINING COMBRETASTATIN DERIVATIVES, PREPARATION AND USE THEREOF | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) | 2011-03-16 | — | — | EP | claimed |
| US-7838706-B2 | Preparation and the use of ethoxy combretastatins and their prodrugs | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2010-11-23 | — | — | US | claimed |
| US-7786098-B2 | Fluoroalkoxycombretastatin derivatives, method for producing the same and use thereof | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD. (CN) | 2010-08-31 | — | — | US | claimed |
| US-20090170956-A1 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2009-07-02 | — | — | US | claimed |
| EP-2065358-A1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) | 2009-06-03 | — | — | EP | claimed |
| EP-2025661-A1 | FLUOROALKYLOXY-CONTAINING COMBRETASTATIN DERIVATIVES, PREPARATION AND USE THEREOF | Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) | 2009-02-18 | — | — | EP | claimed |
| US-20080306027-A1 | Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-11 | — | — | US | claimed |
| CN-101139358-A | Ethoxy combretastatin and preparation and use of its prodrug | ZHEJIANG DADE PHARMACEUTICAL C (CN) | 2008-03-12 | — | — | CN | claimed |
| CN-101085743-A | Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof | ZHEJIANG DADE PHARMACEUTICAL C (CN) | 2007-12-12 | — | — | CN | claimed |
| EP-1497255-A2 | METHOD FOR PREPARING COMBRETASTATINS | Aventis Pharma S.A. (FR) | 2005-01-19 | — | — | EP | claimed |
| US-6759555-B2 | CONDENSING (3,4,5-TRIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE WITH 3-NITRO-4-METHOXYBENZALDEHYDE, REDUCING THE NITRO INTERMEDIATE TO FORM 2-METHOXY-5-(2-(3,4,5-TRIMETHOXYPHENYL)-ETHENYL)ANILINE | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | claimed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | claimed |
| WO-2003084919-A2 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| CN-113501783-B | Erianin heterocyclic derivative and preparation method and application thereof | 上海应用技术大学 | 2022-11-15 | — | — | CN | disclosed |
| CN-113501783-A | Erianin heterocyclic derivative and preparation method and application thereof | 上海应用技术大学 | 2021-10-15 | — | — | CN | disclosed |
| US-10993437-B2 | Anti-microbial polymer incorporating a quaternary ammonium group | CHEMGREEN INNOVATION INC. (CA) | 2021-05-04 | — | — | US | disclosed |
| WO-2017049402-A1 | MULTI-FUNCTIONAL ANTI-MICROBIAL POLYMERS AND COMPOSITIONS CONTAINING SAME | GHANDI KHASHAYAR (CA) | 2017-03-30 | — | — | WO | disclosed |
| US-9487482-B2 | 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-11-08 | — | — | US | disclosed |
| EP-2350030-B9 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-10-26 | — | — | EP | disclosed |
| EP-3064204-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| EP-2350030-B1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-04-20 | — | — | EP | disclosed |
| US-20160100578-A1 | Anti-Microbial Polymer Incorporating a Quaternary Ammonium Group | CHEMGREEN INNOVATION INC. (CA) | 2016-04-14 | — | — | US | disclosed |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-12 | — | — | US | disclosed |
| EP-2065358-B1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014201544-A1 | ANTIMICROBIAL POLYMER INCORPORATING A QUATERNARY AMMONIUM GROUP | CHEMGREEN INNOVATION INC. (CA) | 2014-12-24 | — | — | WO | disclosed |
| US-8883809-B2 | Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-11 | — | — | US | disclosed |
| WO-2013084150-A1 | NOVEL CRYSTAL FORM OF (2S)-2-AMINO-3-HYDROXY-N-[2-METHOXY-2-[(1Z)-2-(3,4,5-TRIMETHOXYPHENYL)ETHENYL]PHENYL]PROPANAMIDE AND METHOD OF PREPARATION THEREOF | SANOFI (FR) | 2013-06-13 | — | — | WO | disclosed |
| EP-2562154-A1 | Method for preparing combretastatin | SANOFI (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Redearch (IN) | 2012-11-08 | — | — | US | disclosed |
| EP-2507218-A1 | COMBRETASTATIN DERIVATIVE PREPARATION METHOD | SANOFI (FR) | 2012-10-10 | — | — | EP | disclosed |
| CN-101139358-B | Ethoxy combretastatin and preparation and use of its prodrug | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD | 2011-10-12 | — | — | CN | disclosed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011067538-A1 | COMBRETASTATIN DERIVATIVE PREPARATION METHOD | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | disclosed |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| EP-2025661-B1 | FLUOROALKYLOXY-CONTAINING COMBRETASTATIN DERIVATIVES, PREPARATION AND USE THEREOF | ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD (CN) | 2011-03-16 | — | — | EP | disclosed |
| US-7838706-B2 | Preparation and the use of ethoxy combretastatins and their prodrugs | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2010-11-23 | — | — | US | disclosed |
| US-7786098-B2 | Fluoroalkoxycombretastatin derivatives, method for producing the same and use thereof | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD. (CN) | 2010-08-31 | — | — | US | disclosed |
| US-20090170956-A1 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | ZHEJIANG DADE PHARMACEUTICAL GROUP CO. LTD (CN) | 2009-07-02 | — | — | US | disclosed |
| EP-2065358-A1 | THE PREPARTION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) | 2009-06-03 | — | — | EP | disclosed |
| EP-2025661-A1 | FLUOROALKYLOXY-CONTAINING COMBRETASTATIN DERIVATIVES, PREPARATION AND USE THEREOF | Zhejiang Dade Pharmaceutical Group Co., Ltd. (CN) | 2009-02-18 | — | — | EP | disclosed |
| US-20080306027-A1 | Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2008-12-11 | — | — | US | disclosed |
| EP-1976505-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | Abraxis BioScience, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| CN-101139358-A | Ethoxy combretastatin and preparation and use of its prodrug | ZHEJIANG DADE PHARMACEUTICAL C (CN) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007059118-A1 | COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1497255-A2 | METHOD FOR PREPARING COMBRETASTATINS | Aventis Pharma S.A. (FR) | 2005-01-19 | — | — | EP | disclosed |
| US-6759555-B2 | CONDENSING (3,4,5-TRIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE WITH 3-NITRO-4-METHOXYBENZALDEHYDE, REDUCING THE NITRO INTERMEDIATE TO FORM 2-METHOXY-5-(2-(3,4,5-TRIMETHOXYPHENYL)-ETHENYL)ANILINE | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084919-A2 | METHOD FOR PREPARING COMBRETASTATINS | AVENTIS PHARMA S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
| CN-1035996-C | Stilbene derivatives and carcinostatics containing them | AJINOMOTO KK (JP) | 1997-10-01 | — | — | CN | disclosed |
| CN-1105967-A | Stilbene derivatives and carcinostatics containing them | AJINOMOTO KK (JP) | 1995-08-02 | — | — | CN | disclosed |
| WO-1992016486-A1 | SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF | ASTON MOLECULES LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016486-A1 | SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF | ASTON MOLECULES LIMITED (GB) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160100578-A1 | Anti-Microbial Polymer Incorporating a Quaternary Ammonium Group | ARG1, PCNA, ARG2 | PTGS2 1793/4885TUBB4A 1430/4885TUBB 518/4885 |
| US-10993437-B2 | Anti-microbial polymer incorporating a quaternary ammonium group | ARG1, PCNA, ARG2 | PTGS2 1793/4885TUBB4A 1430/4885TUBB 518/4885 |
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NDUFAF1, TOP1, COX4I1 | PTGS2 3862/4885TUBB4A 67/4885TUBB 161/4885 |
| US-20080306027-A1 | Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof | TUBB, TUBB1, TUBB3 | PTGS2 4292/4885TUBB4A 7/4885TUBB 1/4885 |
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | PTGS2 34/4885TUBB4A 1286/4885TUBB 709/4885 |
| US-20090170956-A1 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS | PHOSPHO1, TUBB3, TYMP | PTGS2 2545/4885TUBB4A 10/4885TUBB 4/4885 |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | PCSK9, PCSK7, HMGCR | PTGS2 2842/4885TUBB4A 1410/4885TUBB 1639/4885 |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | MCL1, HCCS, CASP3 | PTGS2 1752/4885TUBB4A 344/4885TUBB 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.